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Abstract
Purpose—The Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-
signaling pathway is involved in immune function and cell growth; genetic variation in this 
pathway could influence breast cancer risk.
Methods—We examined 12 genes in the JAK/STAT/SOCS-signaling pathway with breast 
cancer risk and mortality in an admixed population of Hispanic (2111 cases, 2597 controls) and 
non-Hispanic white (1481 cases, 1585 controls) women. Associations were assessed by 
Indigenous American (IA) ancestry.
Results—After adjustment for multiple comparisons, JAK1 (3 of 10 SNPs) and JAK2 (4 of 11 
SNPs) interacted with body mass index (BMI) among pre-menopausal women, while STAT3 (4 of 
5 SNPs) interacted significantly with BMI among post-menopausal women to alter breast cancer 
risk. STAT6 rs3024979 and TYK2 rs280519 altered breast cancer-specific mortality among all 
women. Associations with breast cancer-specific mortality differed by IA ancestry; SOCS1 
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rs193779, STAT3 rs1026916, and STAT4 rs11685878 associations were limited to women with 
low IA ancestry and associations with JAK1 rs2780890, rs2254002, and rs310245 and STAT1 
rs11887698 were observed among women with high IA ancestry. JAK2 (5 of 11 SNPs), SOCS2 
(1of 3 SNPs), and STAT4 (2 of 20 SNPs) interacted with cigarette smoking status to alter breast-
cancer specific mortality. SOCS2 (1 of 3 SNPs) and all STAT3, STAT5A, and STAT5B SNPs 
significantly interacted with use of aspirin/NSAIDs to alter breast cancer-specific mortality.
Conclusions—Genetic variation in the JAK/STAT/SOCS pathway was associated with breast 
cancer-specific mortality. The proportion of SNPs within a gene that significantly interacted with 
lifestyle factors lends support for the observed associations.
Keywords
Breast Cancer; Breast cancer-specific mortality; JAK/STAT/SOCS; polymorphisms; BMI; 
cigarette smoking; aspirin/NSAIDs
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling 
pathway is involved in immune function and cell growth and differentiation[1, 2]. The JAK 
family consists of four non-receptor protein tyrosine kinases, JAK1, JAK2, JAK3, and 
TYK2. Of these, JAK1, JAK2, and TYK2 are expressed ubiquitously in mammals [3]. Once 
activated by cytokines, JAKs serve as docking sites for signaling molecules such as STATs. 
Activated STATs translocate from the cytoplasm to the nucleus where they increase the 
transcription rate of several genes. STAT1 and STAT2 were first identified as contributing 
to activation of genes involved in immune response [4]. STAT5 was first described in the 
mammary gland and has considerable specificity for mammary gland development [5]. 
Altogether, seven STATS have been identified in mammalian cells, STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b, and STAT6 [6]. STAT signaling has been shown to be 
important for mammary cell survival and tumorigenesis [6]. It has also been suggested that 
expression of STATs are associated with unique breast cancer subtypes defined by estrogen 
receptor (ER) and progesterone receptor (PR) status [7].
Cytokines up-regulate suppressors of cytokine signaling (SOCS) that inhibit the activity of 
JAKs and STATs [8]. Thus, research targeting an understanding of the JAK/STAT/SOCS 
signaling pathway often has involved the interaction between JAK/STAT/SOCS with 
cytokines. STAT1 and STAT2 were first identified from work involving downstream events 
of receptor binding of interferon γ (IFNγ) on transcriptional activation of genes involved in 
immune response[4]. Pro-inflammatory cytokines, such as IL-6 have been shown to up-
regulate STAT proteins [4, 9, 10]. Both JAK1 and JAK2 are important for cytokines through 
use of the shared receptor subunits; IL-6 is an important pro-inflammatory cytokine that uses 
these receptors since they are essential for cytokine signaling [11]. JAK2 is essential for 
hormone-like cytokine signaling, including prolactin signaling [11].
This study builds on our previous work that has evaluated breast cancer associations with 
genetic variants in cytokines among women with diverse genetic ancestry. We have shown 
that breast cancer risk and mortality as well as risk associated with IL6 and other cytokine 
SNPs differ by Indigenous American (IA) ancestry [12, 13]. Thus, it is reasonable to 
hypothesize that breast cancer associations with genetic variation in JAK/STAT/SOCS 
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genes may also vary by IA ancestry. Given previous work that suggest these genes may have 
unique ER/PR associations, we evaluated associations by ER/PR tumor subtype. 
Additionally, we evaluated the association of these genes with survival since one of their 
functions is to promote cell differentiation and metastases [14]. Since diet and lifestyle 
factors that are associated with inflammation may modify associations with these genes, we 
evaluate interaction of these genes with a dietary oxidative balance score, body mass index 
(BMI), cigarette smoking status, and use of aspirin and non-steroidal anti-inflammatory 
drugs (NSAIDs).
Methods
The Breast Cancer Health Disparities Study includes participants from three population-
based case-control studies [15], the 4-Corners Breast Cancer Study (4-CBCS) [16], the 
Mexico Breast Cancer Study (MBCS)[17], and the San Francisco Bay Area Breast Cancer 
Study (SFBCS) [18, 19], who completed an in-person interview and who had a blood or 
mouthwash sample available for DNA extraction. Information on exposures was collected 
up to the referent year, defined as the calendar year before diagnosis for cases or before 
selection into the study for controls. 4-CBCS participants were between 25 and 79 years; 
MBCS participants were between 28 and 74 years; and SFBCS participants were between 35 
to 79 years. All participants signed informed written consent prior to participation; the 
Institutional Review Board for Human Subjects at each institution approved the study.
Data Harmonization
Data were harmonized across all study centers and questionnaires as previously described 
[15]. Women were classified as either pre-menopausal or post-menopausal based on 
responses to questions on menstrual history. Pre-menopausal women were those who 
reported still having periods during the referent year. Post-menopausal women were those 
who reported either a natural menopause or if they reported taking hormone therapy (HT) 
and were still having periods or were at or above the 95th percentile of age for those who 
reported having a natural menopause (i.e., ≥ 12 months since their last period). Women in 4-
CBCS and SFBCS were asked to self-identify their race/ethnicity and were classified as 
non-Hispanic white (NHW), Hispanic, Native American (NA) or a combination of these 
groups. Women in MBCS were not asked their race or ethnicity and were combined with 
U.S. Hispanics/NAs in the analyses.
Lifestyle variables included BMI calculated as self-reported weight (kg) during the referent 
year divided by measured height squared (m2) and categorized as normal (<25 kg/m2), 
overweight (25–29.9 kg/m2), or obese (≥30 kg/m2). Regular cigarette smoking was 
evaluated as current, former, or never, where regular was defined as having smoked one or 
more cigarettes for six months or longer in 4-CBCS and SFBCS (data available for a subset 
of subjects only) or having smoked 100 or more cigarettes in MCBCS. A dietary oxidative 
balance score (DOBS) that included nutrients with anti- or pro-oxidative properties was used 
[20]. Dietary information was collected via a computerized validated diet history 
questionnaire in 4-CBCS [12, 21], a 104-item semi-quantitative Food Frequency 
Questionnaire (FFQ) in MBCS [22], and a modified version of the Block Food Frequency 
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Questionnaire in SFBCS [23]. Alcohol consumption was based on long-term use; 
consumption during the referent year was used for a subset of SFBCS women without 
information on long-term use. Regular use of aspirin or NSAIDS defined as three or more 
times a week for at least one month was available for the 4-CBCS only. A history of 
diabetes was defined as ever being told by a health care provider that you had diabetes or 
high blood sugar (not available for all SFBCS participants).
Genetic Data
DNA was extracted from either whole blood (n=7287) or mouthwash (n=634) samples. 
Whole genome amplification (WGA) was applied to the mouthwash-derived DNA samples 
prior to genotyping. TagSNPs were selected to characterize the genetic variation using the 
following parameters: linkage disequilibrium (LD) blocks were defined using a Caucasian 
LD map and an r2=0.8; minor allele frequency (MAF) >0.1; range= −1500 bps from the 
initiation codon to +1500 bps from the termination codon; and 1 SNP/LD bin. Additionally, 
104 Ancestry Informative Markers (AIMs) were used to distinguish European and 
Indigenous American (IA) ancestry [15]. All markers were genotyped using a multiplexed 
bead array assay format based on GoldenGate chemistry (Illumina, San Diego, California. In 
the current analysis we evaluated tagSNPs for JAK1 (10 SNPs), JAK2 (11 SNPs), SOCS1 (2 
SNPs), SOCS2 (3 SNPs), STAT1 (15 SNPs), STAT2 (2 SNPs), STAT3 (5 SNPs), STAT4 (20 
SNPs), STAT5A (2 SNPs), STAT5B (3 SNPs), STAT6 (6 SNPs), TYK2 (4 SNPs). Online 
Supplement 1 provides a description of these genes and SNPs; online supplement 2 
describes LD structure of these genes.
Tumor Characteristics and Survival
Data on estrogen receptor (ER) and progesterone receptor (PR) tumor status and survival 
were available for cases from 4-CBCS and SFBCS only. Cancer registries in Utah, 
Colorado, Arizona, New Mexico, and California provided information on stage at diagnosis, 
months of survival after diagnosis, cause of death, and ER and PR status. Surveillance 
Epidemiology and End Results (SEER) disease stage was categorized as local, regional, or 
distant.
Statistical Methods
Genetic ancestry estimation—The program STRUCTURE was used to estimate 
individual ancestry for each study participant assuming two founding populations [24, 25]. 
A three-founding population model was assessed but did not fit the population structure. 
Participants were classified by level of percent IA ancestry (≤28%, >28–70%, and >70%), 
based on the distribution of genetic ancestry in the control population [15].
SNP Associations—Genes and SNPs were assessed for their association with breast 
cancer risk overall, by strata of IA ancestry, and by menopausal status in the whole 
population and by ER/PR status for the 4-CBCS and SFBCS. All statistical analyses were 
performed using SAS version 9.4 (SAS Institute, Cary, NC). Logistic regression models 
were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for breast cancer 
risk associated with SNPs, adjusting for study, BMI in the referent year, and parity as 
categorical variables and age (five-year categories) and genetic ancestry as continuous 
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variables. Associations with SNPs were assessed assuming a co-dominant model. Based on 
the initial assessment, SNPs that appeared to have a dominant or recessive mode of 
inheritance were evaluated with those inheritance models in subsequent analyses. For 
stratified analyses, the p value was based on the Wald chi-square test comparing the 
homozygote rare to the homozygote common when presenting the co-dominant model. The 
multinomial p value reported for ER/PR status using the glogit link in the logistic procedure 
compares unique associations by tumor phenotype. Adjustments for multiple comparisons 
within the gene used the step-down Bonferroni correction, taking into account the degree of 
correlation of the SNPs within genes using the SNP spectral decomposition method 
proposed by Nyholt [26] and modified by Li and Ji [27]. An unadjusted p value of <0.05 
was considered statistically significant; results are presented for those where the multiple 
comparison adjusted p value was <0.15 and are noted as being marginally associated.
Interactions—We assessed gene by environment interactions for lifestyle factors that 
could influence candidate genes given their potential involvement in inflammation, 
including BMI (separately for pre- and post-menopausal women given differences in risk 
associated with BMI by menopausal status), smoking (current, former, or never smokers), 
dietary oxidative balance score (DOBS), and regular use of aspirin/NSAID (for 4-CBCS 
participants only). DOBS was based on each individual’s intake of anti-oxidants (vitamin C, 
vitamin E, beta carotene (data for beta carotene were not available for MBCS), folic acid, 
and dietary fiber) and pro-oxidants (alcohol). Nutrients were evaluated per 1000 calories and 
the DOBS was based on study-specific distributions given the different dietary 
questionnaires used. Alcohol consumption was classified into three levels: the top 25th 
percentile of consumption, all other drinkers, and non-drinkers. The DOBS ranges from low 
levels (first quartile) of exposure to anti-oxidants or high exposure to pro-oxidants (fourth 
quartile) to high levels of anti-oxidants (fourth quartile) and low exposure to pro-oxidants 
(non-drinkers). Tests for interactions were evaluated using Wald one degree of freedom (1-
df) chi-square tests.
Survival Analysis—Survival months were calculated based on month and year of 
diagnosis and month and year of death or last contact. Survival updates were received in the 
winter of 2013 that included complete survival surveillance through December of 2012. 
Associations between SNPs and breast cancer-specific mortality among cases with a first 
primary invasive breast cancer were evaluated using Cox proportional hazards models to 
obtain multivariate hazard ratios (HR) and 95% confidence CI. Individuals were censored 
when they died of causes other than breast cancer or were lost to follow-up. We present 
Wald p values for all women and by ancestry strata based on the comparison between the 
homozygote rare and common genotype when presenting the co-dominant inheritance model 
using models adjusted for age, study center, genetic ancestry, and SEER stage. Since 
survival data were not available for MBCS, the upper two ancestry strata were combined to 
evaluate survival by genetic ancestry. Interactions between genetic variants and genetic 
ancestry, BMI, cigarette smoking, DOBS, and aspirin/NSAID use with survival were 
assessed using p values from 1-df Wald chi-square tests.
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The majority of women were U.S. Hispanic or Mexican and were slightly younger than U.S. 
NHW women (Table 1). U.S. Hispanic women were more likely to have ER−/PR− tumors 
than NHW women. Approximately 20% of women had died, with 47.6% of deaths being 
from breast cancer among NHW and 55.9% of deaths among U.S. Hispanic women.
Few associations were observed between SNPs in our candidate genes and breast cancer risk 
(Table 2). STAT5B rs6503691 and TYK2 rs280519 were associated with reduced risk among 
women with high IA ancestry (ORCT/TT = 0.63 95% CI 0.41, 0.97, Phet=0.39 and ORAG/GG 
= 0.75 95% CI = 0.58, 0.96, Phet=0.46) and STAT6 rs3024974 (ORCT/TT = 1.15 95 %CI 
1.02, 1.29, Phet=0.71) was associated with increased breast cancer risk overall. More 
associations were observed for specific tumor phenotype, with JAK2 rs1536800 being 
associated with ER−/PR− tumors and STAT3 (4 SNPs) and STAT5A (2 SNPs) and STAT5B 
(1 SNP) associated with ER−/PR+ tumors. These differences were statistically significant 
for JAK2 rs1536800 (Phet=0.03), STAT3 rs8069645 (Phet=0.03), STAT5A 7217728 
(Phet=0.04), and STAT5B rs7218653 (Phet=0.02). No significant differences in association 
were detected by menopausal status (data not shown).
BMI was the main lifestyle factor that interacted with these genes to alter risk of breast 
cancer (Table 3). JAK1 (3 SNPs) and JAK2 (4 SNPs) interacted with BMI among pre-
menopausal women, with the majority of the differences observed among those who were 
obese. Among post-menopausal women, STAT3 (4 SNPs) interacted with BMI to alter breast 
cancer risk, with the majority of the differences observed among those with normal BMI. 
Additionally, interactions were seen between STAT1 (2 SNPs) and STAT4 (1 SNP) and 
DOBS. We also assessed interaction between IL6 and its receptor and JAK/STAT/SOC 
pathway genes and observed several significant interactions although after adjustment for 
multiple comparisons none of the associations were statistically significant (data not shown).
STAT6 rs3024979 and TYK2 rs280519 were associated with breast cancer-specific mortality 
overall (Table 4). However, most associations were restricted to either low or high IA 
ancestry group. Among women with low IA ancestry, SOCS1 rs193779, STAT3 rs1026916, 
and STAT4 rs11685878 were associated with breast cancer-specific mortality. Among 
women with high IA ancestry (JAK1 rs2780890, rs2254002, and rs310245) and STAT1 
rs11887698 were associated with breast cancer-specific mortality. Additionally, JAK2 (5 
SNPs), SOCS2 (1 SNP), and STAT4 (2 SNPs) interacted with cigarette smoking status to 
alter breast cancer-specific mortality (Table 5), with associations predominantly observed 
among current smokers. STAT1 rs2030171 and STAT5B rs9900213 interacted with DOBS to 
alter breast cancer-specific mortality (Table 5). Interactions also were seen between SOCS2 
(1 SNP), STAT3 (5 SNPs), STAT5A (2 SNPs), and STAT5B (3 SNPs) and regular use of 
aspirin/NSAIDs. No significant interactions with BMI were observed after adjustment for 
multiple comparisons.
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Among genes within the JAK/STAT/SOC-signaling pathway, we observed several 
associations between SNPs and breast cancer mortality, and a few significant associations 
with risk of breast cancer, irrespective of genetic ancestry or ER/PR tumor subtypes. 
However, lifestyle factors that influence inflammation interacted with these genes to alter 
breast cancer risk and mortality. Specifically, BMI and DOBS interacted with these genes to 
alter breast cancer risk, while cigarette smoking and aspirin/NSAID use interacted with them 
to influence breast cancer-specific mortality. The proportion of SNPs within a gene that 
significantly interacted with DOBS and lifestyle factors was considerably greater than by 
chance, lending support for the observed associations.
Although it is reasonable to genes could help explain differences in breast cancer incidence 
rates when comparing populations with high vs. low IA ancestry, our results provide little 
support for that hypothesis. Others have suggested that this pathway has unique associations 
with tumor phenotype and estrogen [7, 28–30], but we found minimal support for 
differences in associations by ER/PR subtype. The majority of associations were with ER
−/PR+ tumors, and although statistically significant after adjustment for multiple 
comparisons, there were few individuals with that phenotype and therefore estimates of 
association were imprecise even though they were statistically significant.
Of interest are the consistent associations observed for the interaction of BMI with JAK1 (3 
out of 10 SNPs) and JAK2 (4 out of 11 SNPs) for pre-menopausal breast cancer risk and 
with STAT3 (4 of 5 SNPs) for post-menopausal breast cancer risk. The number of SNPs 
within genes that were associated with breast cancer risk was greater than one would expect 
by chance. One explanation for the interactions between BMI and JAK1, JAK2, and STAT3 
could be the strong correlation between leptin and BMI. Although leptin is mainly produced 
by white adipocytes, it is also produced by mammary epithelium. The leptin receptor is a 
class I cytokine receptor that acts through JAK and STATs and the JAK/STAT pathway is 
one of the main signaling cascades activated by leptin [31]. Additionally, STAT3 
specifically has been shown to influence energy homeostasis [32, 33]. Activation of the 
JAK/STAT pathway also can promote tumor growth and induce inflammation as well as 
regulate other genes that control cell proliferation, differentiation, tumor development, and 
cell survival.
The JAK/STAT pathway is critical for cell development, cell survival, cell proliferation, and 
apoptosis; our results suggest genetic variation in these genes is important for breast cancer-
specific mortality. We observed stronger estimates of association and more consistent 
associations across genes, and SNPs within those genes, with breast cancer-specific 
mortality than with breast cancer risk. Thus, it is possible that these genes function as tumor 
promoters, as has been suggested [6, 34]. The strongest and most consistent associations 
were observed for the interaction between cigarette smoking and aspirin/NSAID use with 
JAK2, STAT3, STAT5a, and STAT5b and to a lesser extent with SOSC2 (rs3816997 which 
interacted with both cigarette smoking and aspirin/NSAIDs use) to influence breast cancer-
specific mortality. The JAK/STAT signaling pathway is activated when cytokines are bound 
to their receptors while SOCs suppresses the signaling. Nicotine has been shown to activate 
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the JAK2/STAT3 pathway [35], which in this case appears to promote tumor progression 
depending on JAK2/STAT3 genotype.
Regular use of aspirin/NSAIDs interacted with all SNPs evaluated for STAT3 (5), STAT5A 
(2), and STAT5B (3) to alter breast cancer-specific mortality. STAT3 has been shown to be a 
promoter of tumor invasiveness and angiogenesis [6]. Activation of STAT5, which was first 
recognized as mammary gland factor, results in regulation of several genes involved in cell 
apoptosis, survival, and proliferation [14]. It has been shown that aspirin regulates apoptosis 
by down-regulating the IL6-STAT3 pathway [36] and that the epidermal growth factor 
induces COX2 through STAT5 signaling [37] thus providing biological support for our 
observations.
We believe that these findings are unique and have found no reference to the importance of 
these genes in the literature or in GWAS studies of breast cancer. Our candidate pathway 
approach has enabled us to identified important genes based on their biological function. 
Furthermore our ability to evaluate interaction with diet and lifestyle factors has enhanced 
our understanding of these genes and how they influence breast cancer risk and mortality.
This study has both strengths and limitations. The population represents a large genetically 
diverse population that includes extensive data on diet and lifestyle factors along with 
genetic data, ER/PR status, and vital status. However, ER/PR status and vital status were 
available only for the U.S. based studies. We used a tag-SNP approach to characterize 
genetic variation in these genes, although other SNPs could be important that were not 
analyzed. We adjusted for multiple comparisons within our candidate genes, although we 
cannot exclude the possibility of chance observations. However, the number of SNPs within 
genes for which we observed associations further indicates that these observations may be 
more than chance findings. Nevertheless, we encourage others to replicate our findings, 
especially those that pertain to survival, given their implication for treatment modalities as 
has been suggested [38].
In conclusion, our findings suggest that genetic variation in the JAK/STAT/SOCS signaling 
pathway is important for breast cancer-specific mortality. Of note is the consistent and 
stronger interaction observed between JAK2, SOCS2, STAT3 and STAT5 and cigarette 
smoking and use of aspirin/NSAIDs to modify breast cancer-specific mortality. Additionally 
JAK1, JAK2, and STAT3 interacted with BMI to modify risk of developing breast cancer. 
Given the potential importance of these findings on modalities such as aspirin/NSAIDS to 
improve survival on a subset of women, replication of these findings in other populations is 
needed.
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